New Frontiers in 1L BTC Treatment

Learn-Objetives
Learning Objectives

  1. Recognize the efficacy and safety data of IO in BTC  (Topaz-1 data)
  2. Discuss clinical perspectives on the data, in the real-world setting; outcomes and success stories
  3. Apply best practices to optimize patient identification and treatment selection in BTC

calendarTuesday, December 31, 2023

7:00 pm -8:00 pm ET

Book Event

Available Tickets: Unlimited
The ticket is sold out. You can try another ticket or another date.

personAbout the Faculty

Jan-Willem Henning, MBChB, FRCPC

Ravi Ramjeesingh, MD, PhD, FRCPC

Panelist

Dr. Ramjeesingh joined the Division of Medical Oncology at Dalhousie University in May 2015 as a staff physician and Associate Professor. He completed his Ph.D in cancer research in 2004, and his doctor of medicine in 2008 at the University of Toronto. He then subsequently completed his Internal Medicine and Medical Oncology residencies at Queen’s University before completed a clinical trials methodology fellowship at the Canadian Clinical Trials Group (CCTG) in Kingston, Ontario where he also received a CAMO-CIHR fellowship. His main clinical expertise is in the areas of hepatobiliary cancers including pancreatic and hepatocellular carcinoma, and breast cancer. He is currently the chair of the HPB Disease site group in Nova Scotia and is the Director of Research in the division of medical oncology. His research activities and interests are in the fields of Health service delivery, and translational research in Oncology. He has been awarded the Department of Medicine Research Excellent award in 2017 and the DOM Excellence in Medical Education award in 2018.

Joyce O'Shaughnessy, MD

Milind Javle, MD

Panelist

Dr. Milind Javle is the Hubert L and Olive Stringer Professor of GI Medical Oncology at MD Anderson Cancer Center, Houston, Texas where he leads the Biliary Cancer Program. He graduated from Grant Medical College in India, did his residency at SUNY Buffalo and Oncology Fellowship at Roswell Park Cancer Center, where he specialized in GI Cancers. He has been at MD Anderson since 2007 and has built a reputation as a leader in GI Oncology, particularly biliary and pancreatic cancers. He has over 200 publications in the field, has extensive research support from DOD, NIH, Foundations, Industry and Philanthropy. He is the current Chair of the NCI Task Force in Hepatobiliary Cancers, the former Chair of the International Cholangiocarcinoma Research Network, Vice President of the Cholangiocarcinoma Foundation and Co-Chair of the SWOG Hepatobiliary Committee.

Joyce O'Shaughnessy, MD

Kim Ma

Panelist

Dr. Kim Ma studied hematology, oncology, and internal medicine at McGill University in Montréal, Canada. Dr. Ma is a recipient of the J.W. McConnell Award, the Student Research Award F.R.S.Q., the Millennium Award of Excellence, the McGill Entrance Award, and the Science Award at McGill University. She has a special interest in thrombosis, and thus focuses much of her research in this area. Most recently, Dr. Ma helped investigate the ELOPE Study, which looked at serial imaging after pulmonary embolism and correlation with functional limitations.

Sponsorship

This program has been made possible through unrestricted support from AstraZeneca.

81336191966